Virginia · 2026 Regular Session · Bill
HB 736: Health insurance; required provisions regarding prior authorization for prescription drugs.
Enacted Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
HB 736 is a bill introduced in the Virginia House on January 13, 2026. According to its official title, it concerns: Health insurance; required provisions regarding prior authorization for prescription drugs. Primary sponsor: Michelle Lopes Maldonado. It lists 1 additional sponsor. Most recent recorded action (April 6, 2026): Acts of Assembly Chapter text (CHAP0213).
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official summary
Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.
Health insurance; carrier contracts; required provisions regarding prior authorization for prescription drugs. Amends existing required provisions for health carrier contracts related to prior authorizations for prescription drugs. Current law requires that if prior authorization is approved for prescription drugs and such prescription drugs have been scheduled, provided, or delivered to the patient consistent with the authorization, health carriers may not revoke, limit, condition, modify, or restrict that authorization except in certain circumstances. The bill requires this limitation on carriers to apply for the duration of the authorization, which the bill requires to be a minimum of six months for initial authorizations and a minimum of 12 months for continued authorizations. The bill adds circumstances under which a prior authorization may be revoked, limited, conditioned, modified, or restricted by a carrier, including (i) a final action by the U.S. Food and Drug Administration, other regulatory agencies, or the manufacturer communicating a patient efficacy issue that would affect the authorization and (ii) when additional safety and efficacy monitoring is clinically appropriate or recommended by the U.S. Food and Drug Administration, other regulatory agencies, or the manufacturer.
Sponsors
Sponsors by party (alphabetical): Democratic 1
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Michelle Lopes Maldonado | Primary sponsor | Not applicable (committee) | — | — |
| Amy Laufer | Co-sponsor | Democratic | House | 55 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- Acts of Assembly Chapter text (CHAP0213)
- Approved by Governor-Chapter 213 (effective 7/1/2026)
- Governor's Action Deadline 11:59 p.m., April 13, 2026
- Enrolled Bill communicated to Governor on March 14, 2026
- Signed by President
- Signed by Speaker
- Fiscal Impact Statement from Department of Planning and Budget (HB736)
- Bill text as passed House and Senate (HB736ER)
- Enrolled
- Passed Senate (39-Y 0-N 0-A)
- Read third time
- Passed by for the day (Voice Vote)
Showing 12 most recent of 31 actions. Full history